Skip to main content
SpringerLink
Log in

Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to investigate the effects of soy isoflavones on serum markers of bone formation and resorption in peritoneal dialysis (PD) patients.

Methods

In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the soy isoflavone or the placebo group. The patients in the soy isoflavone group received 100 mg soy isoflavones daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of the 8th week, 7 ml of blood was obtained from each patient after a 12- to 14-h fast and serum concentrations of bone formation markers (osteocalcin and bone alkaline phosphatase), bone resorption markers [N-telopeptide and receptor activator of nuclear factor kappa B ligand (RANKL)], and osteoprotegerin as an inhibitor of bone resorption were measured.

Results

Serum N-telopeptide concentration decreased significantly up to 27% in the soy isoflavone group at the end of week 8 compared to baseline (P = 0.003). Also, serum RANKL concentration reduced significantly up to 17% in the soy isoflavone group at the end of week 8 compared to baseline (P = 0.03). These bone resorption markers did not significantly change in the placebo group during the study. There were no significant differences between the two groups in mean changes of serum osteocalcin, bone alkaline phosphatase, and osteoprotegerin.

Conclusion

This study indicates that daily administration of 100 mg soy isoflavone supplement to PD patients reduces serum N-telopeptide and RANKL which are two bone resorption markers.

ClinicalTrials.gov

NCT03773029, 2018.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kombaba H, Tanaka M, Fukagawa M (2008) Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Int Med 47(11):989–994

    Article  Google Scholar 

  2. Lu KC, Wu CC, Yen JF, Liu WC (2014) Vascular calcification and renal bone disorders. Sci World J 2014:637065

    Google Scholar 

  3. Delmez JA, Kaye M (2001) Bone disease. In: Daugirdas JT, Blake PG, Ing TS (eds) Handbook of dialysis, 3rd edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  4. Heaf JG (2015) Chronic kidney disease-mineral bone disorder in the elderly peritoneal dialysis patient. Perit Dial Int 35(6):640–644

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cozzolino M, Ureña-Torres P, Vervloet MG et al (2014) Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant 29(10):1815–1820

    Article  CAS  PubMed  Google Scholar 

  6. Evenepoel P, Cavalier E, D'Haese PC (2017) Biomarkers predicting bone turnover in the setting of CKD. Curr Osteoporos Rep 15(3):178–186

    Article  PubMed  Google Scholar 

  7. Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, Eastell R (2018) Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 29(5):1557–1565

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yamada S, Tsuruya K, Yoshida H et al (2013) The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis. Clin Endocrinol (Oxf) 78(6):844–851

    Article  CAS  Google Scholar 

  9. Hamano T, Tomida K, Mikami S et al (2009) Usefulness of bone resorption markers in hemodialysis patients. Bone 45(Suppl 1):S19–25

    Article  CAS  PubMed  Google Scholar 

  10. Vervloet MG, Brandenburg VM, CKD-MBD working group of ERA-EDTA (2017) Circulating markers of bone turnover. J Nephrol 30(5):663–670

    Article  PubMed  PubMed Central  Google Scholar 

  11. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79(5):727–747

    Article  CAS  PubMed  Google Scholar 

  12. Harkness LS, Fiedler K, Sehgal AR, Oravec D, Lerner E (2004) Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health (Larchmt) 13(9):1000–1007

    Article  Google Scholar 

  13. Roudsari AH, Tahbaz F, Hossein-Nezhad A, Arjmandi B, Larijani B, Kimiagar SM (2005) Assessment of soy phytoestrogens' effects on bone turnover indicators in menopausal women with osteopenia in Iran: a before and after clinical trial. Nutr J 4:30

    Article  PubMed  Google Scholar 

  14. Uesugi T, Fukui Y, Yamori Y (2002) Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study. J Am Coll Nutr 21(2):97–102

    Article  CAS  PubMed  Google Scholar 

  15. Lee H, Choue R, Lim H (2017) Effect of soy isoflavones supplement on climacteric symptoms, bone biomarkers, and quality of life in Korean postmenopausal women: a randomized clinical trial. Nutr Res Pract 11(3):223–231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bandeira F, Costa AG, Soares Filho MA, Pimentel L, Lima L, Bilezikian JP (2014) Bone markers and osteoporosis therapy. Arq Bras Endocrinol Metabol 58(5):504–513

    Article  PubMed  Google Scholar 

  17. Sardiwal S, Magnusson P, Goldsmith DJ, Lamb EJ (2013) Bone alkaline phosphatase in CKD-mineral bone disorder. Am J Kidney Dis 62(4):810–822

    Article  CAS  PubMed  Google Scholar 

  18. Kajarabille N, Díaz-Castro J, Hijano S, López-Frías M, López-Aliaga I, Ochoa JJ (2013) A new insight to bone turnover: role of ω-3 polyunsaturated fatty acids. Sci World J 2013:589641

    Article  Google Scholar 

  19. Nakashima A, Yorioka N, Mizutani T, Yamagata Z, Ueno T, Takasugi N (2005) Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients. Nephron Clin Pract 99(3):c78–c85

    Article  CAS  PubMed  Google Scholar 

  20. Burkart JM, Bargman JM (2009) Adequacy of peritoneal dialysis, including fluid balance. In: Khanna R, Krediet RT (eds) Nolph and Gokal’s textbook of peritoneal dialysis, 3rd edn. Springer, New York

    Google Scholar 

  21. Blake PG, Daugirdas JT (2001) Physiology of peritoneal dialysis. In: Daugirdas JT, Blake PG, Ing TS (eds) Handbook of dialysis, 3rd edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  22. Oreopoulos DG, Rao PS (2001) Assessing peritoneal ultrafiltration, solute transport, and volume status. In: Daugirdas JT, Blake PG, Ing TS (eds) Handbook of dialysis, 3rd edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  23. Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM (2013) The clinical utility of bone marker measurements in osteoporosis. J Transl Med 11:201

    Article  PubMed  PubMed Central  Google Scholar 

  24. Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ (2003) The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol (Oxf) 58(6):704–709

    Article  CAS  Google Scholar 

  25. Kenny AM, Mangano KM, Abourizk RH et al (2009) Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. Am J Clin Nutr 90(1):234–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yu F, Liu Z, Tong Z, Zhao Z, Liang H (2015) Soybean isoflavone treatment induces osteoblast differentiation and proliferation by regulating analysis of Wnt/β-catenin pathway. Gene 573(2):273–277

    Article  CAS  PubMed  Google Scholar 

  27. Bitto A, Burnett BP, Polito F et al (2008) Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. Br J Pharmacol 155(6):896–905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Chen X, Anderson JJB (2002) Isoflavones and bone: Animal and human evidence of efficacy. J Musculoskelet Neuron Interact 2(4):352–359

    CAS  Google Scholar 

  29. Chen WF, Wong MS (2006) Genistein modulates the effects of parathyroid hormone in human osteoblastic SaOS-2 cells. Br J Nutr 95(6):1039–1047

    Article  CAS  PubMed  Google Scholar 

  30. Zoch ML, Clemens TL, Riddle RC (2016) New insights into the biology of osteocalcin. Bone 82:42–49

    Article  CAS  PubMed  Google Scholar 

  31. Taku K, Melby MK, Nishi N, Omori T, Kurzer MS (2011) Soy isoflavones for osteoporosis: an evidence-based approach. Maturitas 70(4):333–338

    Article  CAS  PubMed  Google Scholar 

  32. Epstein S, Traberg H, Raja R, Poser J (1985) Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab 60(6):1253–1256

    Article  CAS  PubMed  Google Scholar 

  33. Takano M, Okano K, Tsuruta Y et al (2011) Correlation of new bone metabolic markers with conventional biomarkers in hemodialysis patients. Clin Investig Med 34(5):E267

    Article  CAS  Google Scholar 

  34. Greenblatt MB, Tsai JN, Wein MN (2017) Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem 63(2):464–474

    Article  CAS  PubMed  Google Scholar 

  35. Ueda M, Inaba M, Okuno S et al (2002) Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 40(4):802–809

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the staff of the peritoneal dialysis centers in Tehran, Iran, for their invaluable assistance, and the staff of the research laboratory of Research Institute for Endocrine Sciences and the nutrition research laboratory of the Faculty of Nutrition and Food Technology for their technical assistance.

Funding

This study was funded by the National Nutrition and Food Technology Research Institute of Iran (Grant number 311-1024).

Author information

Authors and Affiliations

  1. National Nutrition and Food Technology Research Institute, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran

    Zahra Yari & Mina Movahedian

  2. Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, 46, West Arghavan St., Farahzadi Blvd., Shahrak Qods, P. O. Box 19395-4741, Tehran, Islamic Republic of Iran

    Hadi Tabibi

  3. Department of Nephrology, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran

    Iraj Najafi

  4. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran

    Mehdi Hedayati

Authors
  1. Zahra Yari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hadi Tabibi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iraj Najafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehdi Hedayati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mina Movahedian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hadi Tabibi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest in the publication of the above manuscript. In addition, Dr. Hadi Tabibi has received a research grant from the National Nutrition and Food Technology Research Institute of Iran and declares that he has no conflict of interest with this research institute.

Ethical approval

All procedures performed in our study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the Ethics Committee of the National Nutrition and Food Technology Research Institute of Iran.

Informed consent

Written informed consent was obtained from all patients included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yari, Z., Tabibi, H., Najafi, I. et al. Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial. Int Urol Nephrol 52, 1367–1376 (2020). https://doi.org/10.1007/s11255-020-02523-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-020-02523-w

Keywords

Search

Navigation